Cargando…

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapies have been suggested based mostly on experiment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haluzík, Martin, Frolík, Jan, Rychlík, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780627/ https://www.ncbi.nlm.nih.gov/pubmed/24089613 http://dx.doi.org/10.1155/2013/895102

Ejemplares similares

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Effects of DPP4 Inhibitors on Renal Outcomes in Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Dalui, Saikat K., et al.
Publicado: (2021)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
por: Du, Hengzhi, et al.
Publicado: (2020)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
por: Sharma, Ashwani, et al.
Publicado: (2022)

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
por: Chaykovska, Lyubov, et al.
Publicado: (2011)

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma
por: Horie, Kuniko, et al.
Publicado: (2023)

Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2016)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
por: Krejner-Bienias, Alicja, et al.
Publicado: (2021)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
por: Mathur, Vishal, et al.
Publicado: (2023)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Microalbuminuria: causes and implications
por: Singh, Anurag, et al.
Publicado: (2011)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
por: Kubo, Ayano, et al.
Publicado: (2020)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Liraglutide and DPP-4 inhibitors – side effects comparative clinical study
por: TIMOFTE, LUMINIŢA, et al.
Publicado: (2013)

DPP‐4 inhibition and islet function
por: Ahrén, Bo
Publicado: (2011)

Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
por: Zakaria, Esraa M., et al.
Publicado: (2022)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
por: Xue, Jujun, et al.
Publicado: (2020)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8bovs47dgj8or84ppl5192k0cm